Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05267496 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Oscillating Positive Expiratory Pressure Therapy for Patients With Thoracic Neoplasms Undergoing Chest Surgery

Study acronym: AEROBIKA
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 31, 2025 to Dec 31, 2026v5
  2. Study completion date: Dec 31, 2023 to Dec 31, 2025v4
  3. Primary endpoint revisedv3 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 2022 to Feb 28, 2023
    • Study completion date: Jun 2023 to Dec 31, 2023
    • Study description expanded, about 238 words
    • Site details revised
  4. Eligibility criteria shortened, about 1 wordv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized clinical study aims to assess the use of an oscillating positive expiratory pressure device (AEROBIKA) in patients with thoracic neoplasms who undergo chest surgery. The main questions it aims to answer are: If the use of the AEROBIKA device reduces the incidence of atelectasis in oncological patients undergoing lung resection. If the use of the AEROBIKA device reduces hospital readmission and days of hospital stay. Participants who accept to participate will be sorted to receive a conventional rehab therapy (group A), otherwise a conventional rehab therapy plus AEROBIKA device (group B). Researchers will compare patients from group A versus group B to see if patients develop atelectasis.
Trial Details
NCT Number NCT05267496
Lead Sponsor Instituto Nacional de Cancerologia de Mexico
Conditions
(from sponsor)		 Lung Cancer, Mediastinal Tumor, Pleural Tumor
Related terms Lung Neoplasms, Mediastinal Neoplasms, Pleural Neoplasms
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov